SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Teslas scheduled Cybercab/robotaxi launch, alongside reported expansion of unsupervised Austin testing and fleet additions, is driving attention. Traders are divided between bullish expectations that autonomy will accelerate Teslas AI and mobility opportunity and concerns that the event may trigger a buy the rumor, sell the news reversal amid valuation and execution risks.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

Recent strong earnings and BioCrysts profitable Orladeyo franchise are being weighed against unconfirmed buyout speculation and the companys shift toward acquiring external rare-disease assets. Traders remain divided, with bullish investors focused on pediatric Orladeyo growth and future navenibart data, while others cite competition, pipeline uncertainty, low volume, and stagnant price action.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Attention centers on SELLASs event-driven REGAL Phase 3 trial, which remains officially at 78 of 80 events and is nearing the milestone that triggers final efficacy analysis for GPS in AML. Traders are divided between bullish interpretations of the prolonged event accrual and industry comments calling GPS a potential game changer, and bearish concerns about trial design, control-arm survival, and the binary readout risk.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Anticipation of Apples September iPhone launchits first major event under incoming CEO John Ternus, with a possible foldable iPhone and Siri AI upgradesis driving attention and bullish options positioning. Traders debate whether the event can justify the companys valuation, with skeptics citing slowing demand, memory costs, and the risk of a pre-event run-up followed by a sell-the-news reaction.

Zoracles

A sharp price and volume surge has pushed ZORA into focus, with traders citing its small market cap, rising activity and potentially crowded futures shorts as fuel for a short squeeze. Others caution that the move may be a speculative pump-and-dump, leaving the fundamental catalyst unconfirmed.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

U.S.-Iran military escalation, including strikes near the Strait of Hormuz, is the dominant market-related discussion, with traders linking the conflict to higher oil prices, inflation and broader market risk. Supporters argue Trumps Iran and Venezuela energy actions could improve stability and supply, while critics view the war and trade policies as costly, destabilizing and damaging to the economy.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Visas monitoring of Hims & Hers over elevated payment disputes tied to weight-loss subscriptions, alongside ongoing FTC scrutiny, is driving attention and selling pressure. Traders debate whether the issues are temporary growing pains and an overblown reaction or evidence of deeper subscription and compliance risks, while bulls continue to cite the companys telehealth, GLP-1, peptide and AI growth opportunities.

GE Vernova, Inc. engages in the electric power industry. It operates through the following segments: Power, Wind, and Electrification. The Power segment offers design, manufacture, and servicing gas, nuclear, hydro, and steam technologies, providing a critical foundation of dispatchable, flexible, stable, and reliable power. The Wind segment manages wind generation technologies, including onshore and offshore wind turbines and blades. The Electrification segment refers to the grid solutions, power conversion, electrification software, and solar and storage solutions technologies required for the transmission, distribution, conversion, storage, and orchestration of electricity from point of generation to point of consumption. The company was founded November 9, 2021 and is headquartered in Cambridge, MA.

GE Vernova Inc.

A mixed second-quarter earnings reportan earnings miss despite a revenue beat and raised full-year outlookhas driven a sharp selloff and intense debate. Traders are split between viewing the move as a valuation or profit-taking reaction and maintaining the long-term AI power and grid thesis on strong orders, turbine demand, and backlog.

iShares Trust - iShares Expanded Tech-Software Sector ETF

iShares Expanded Tech-Software Sector ETF

A broad rotation into software from semiconductors and AI infrastructure, reinforced by strong results from several major software companies and renewed belief that AI can enhance rather than replace embedded SaaS workflows, is driving attention to IGV. Traders remain divided over whether the move represents durable sector leadership and a technical breakout or a crowded, rate-sensitive rebound vulnerable to renewed AI-disruption fears and profit-taking.

Aduro Clean Technologies, Inc. engages in the manufacture of oils and specialty chemicals using waste plastics. It focuses on hydrochemolytic technology to transform post-consumer polymer waste into a resource for the circular economy. It also develops a novel chemical conversion process to transform waste plastics and low grade renewable oils into renewable fuels and specialty chemicals. The company was founded on January 10, 2018 by Ofer Vicus and William Marcus Trygstad and is headquartered in Sarnia, Canada.

Aduro Clean Technologies Inc

Aduros advance of its ECOCE partnership from feedstock mapping to Hydrochemolytic Technology testing in Mexico is driving attention, alongside ongoing FOAK plant and crude-upgrading milestones. Bulls view the updates as commercialization validation, while skeptics question the economics after years of testing; recent financing and dilution concerns have added volatility despite the positive operational news.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Zenas BioPharma's CEO Purchased 60,000 Company Shares. Here's a Deeper Look at the Transaction.

Key PointsCEO Leon Moulder acquired 60,000 shares for a total value of approximately $1.01 million on May 18, 2026...

Tuesday 5/19 Insider Buying Report: ZBIO, ICFI

As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy -- they expect to make money. So let's look at two noteworthy recent insider buys.

On Monday, Zenas Biopharma's Chief Executive Officer, Leon O. Moulder Jr., made a...

Zenas BioPharma (NASDAQ:ZBIO) Stock Price Up 7.7% - Still a Buy?

Zenas BioPharma (NASDAQ:ZBIO) Shares Up 7.7% - Should You Buy...

Thursday 4/30 Insider Buying Report: ZBIO, PDX

As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy -- they expect to make money. So let's look at two noteworthy recent insider buys.

At Zenas Biopharma, a filing with the SEC revealed that on Wednesday, Chief Executi...

Zenas BioPharma (NASDAQ:ZBIO) Shares Gap Up on Insider Buying Activity

Zenas BioPharma (NASDAQ:ZBIO) Shares Gap Up on Insider Buying Activity...

Leon Moulder, Jr. Buys 25,000 Shares of Zenas BioPharma (NASDAQ:ZBIO) Stock

Zenas BioPharma, Inc. (NASDAQ:ZBIO - Get Free Report) CEO Leon Moulder, Jr. purchased 25,000 shares of the company's stock in a transaction that occurred on Tuesday, April 28th. The shares were...

Zenas BioPharma (NASDAQ:ZBIO) CEO Acquires $616,700.00 in Stock

Zenas BioPharma, Inc. (NASDAQ:ZBIO - Get Free Report) CEO Leon Moulder, Jr. bought 35,000 shares of the stock in a transaction on Wednesday, April 29th. The stock was purchased at an average cost of...

Leon Moulder Jr Purchases 25,000 Shares of Zenas BioPharma (NASDAQ:ZBIO) Stock

Zenas BioPharma, Inc. (NASDAQ:ZBIO - Get Free Report) CEO Leon Moulder, Jr. purchased 25,000 shares of the stock in a transaction that occurred on Tuesday, April 28th. The shares were acquired at an...

Zenas BioPharma, Inc. (NASDAQ:ZBIO) Given Average Rating of "Hold" by Analysts

Zenas BioPharma, Inc. (NASDAQ:ZBIO - Get Free Report) has been given an average rating of "Hold" by the nine brokerages that are presently covering the firm, Marketbeat reports. Two investment...

Zenas BioPharma (NASDAQ:ZBIO) Issues Quarterly Earnings Results

Zenas BioPharma (NASDAQ:ZBIO - Get Free Report) posted its earnings results on Monday. The company reported ($1.10) earnings per share (EPS) for the quarter...

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.

Zenas Biopharma Inc.

Why Is ZBIO Stock Falling Pre-Market Today?

Equity

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '26	--	-$4.54	--	N/A
Q3 '26	-$1.22	--	--	N/A
Q2 '26	-$1.12	-$1.77	-57.71%	MISSED
Q1 '26	-$1.47	-$1.46	0.96%	BEAT
Q4 '25	-$1.00	-$4.54	-353.36%	MISSED

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q3 '26

Historical Earnings